Genzyme's income continues to suffer from costly expenses
This article was originally published in Scrip
Executive Summary
Genzyme's revenue has continued to rise in the third quarter, increasing by 21% to $1.16 billion, driven by double-digit growth in all of its businesses and benefiting by around $31 million from the strengthening of the euro against the dollar. However, the company's income decreased again compared with the same period last year, falling by 25% to $119.6 million.